Innate Pharma: data published in Nature Biotechnology
At Innate Pharma, we are developing a broad portfolio of NK cell engagers via our proprietary ANKET platform, which can address different types of cancer", says Eric Vivier, Chief Scientific Officer of the biopharmaceutical company.
A Phase 1/2 clinical trial, sponsored by Sanofi, evaluating IPH6101/SAR'579 in relapsed or refractory AML, B-cell acute lymphoblastic leukemia or high-risk myelodysplastic syndrome, is currently underway.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction